Symbols / ALGS $7.10 +2.75%
ALGS Chart
About
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 43.69M |
| Enterprise Value | -28.66M | Income | -24.19M | Sales | 2.19M |
| Book/sh | 8.67 | Cash/sh | 12.58 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -1.24 | PEG | — |
| P/S | 19.99 | P/B | 0.82 | P/C | — |
| EV/EBITDA | 0.33 | EV/Sales | -13.11 | Quick Ratio | 3.67 |
| Current Ratio | 3.90 | Debt/Eq | 9.80 | LT Debt/Eq | — |
| EPS (ttm) | -13.54 | EPS next Y | -5.72 | EPS Growth | — |
| Revenue Growth | -73.10% | Earnings | 2026-05-05 | ROA | -69.33% |
| ROE | -196.91% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -129.08% | Profit Margin | 0.00% | Shs Outstand | 5.35M |
| Shs Float | 3.64M | Short Float | 5.51% | Short Ratio | 4.09 |
| Short Interest | — | 52W High | 13.69 | 52W Low | 3.76 |
| Beta | 2.75 | Avg Volume | 62.98K | Volume | 34.00K |
| Target Price | $80.25 | Recom | Strong_buy | Prev Close | $6.91 |
| Price | $7.10 | Change | 2.75% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$80.25
Mean price target
2. Current target
$7.10
Latest analyst target
3. DCF / Fair value
$-168.25
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$7.10
Low
$36.00
High
$175.00
Mean
$80.25
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-07 | init | UBS | — → Buy | $20 |
| 2025-09-12 | reit | HC Wainwright & Co. | Buy → Buy | $50 |
| 2025-03-31 | reit | HC Wainwright & Co. | Buy → Buy | $70 |
| 2025-03-11 | main | HC Wainwright & Co. | Buy → Buy | $70 |
| 2024-11-07 | reit | HC Wainwright & Co. | Buy → Buy | $75 |
| 2024-10-23 | reit | HC Wainwright & Co. | Buy → Buy | $75 |
| 2024-09-20 | reit | HC Wainwright & Co. | Buy → Buy | $75 |
| 2024-08-19 | init | HC Wainwright & Co. | — → Buy | $75 |
| 2023-01-17 | main | Piper Sandler | — → Overweight | $7 |
| 2023-01-06 | up | Piper Sandler | Neutral → Overweight | $3 |
| 2023-01-06 | up | Jefferies | Hold → Buy | $3 |
| 2022-11-03 | main | SVB Leerink | — → Market Perform | $2 |
| 2022-05-05 | down | SVB Leerink | Outperform → Market Perform | $3 |
| 2022-03-23 | main | SVB Leerink | — → Outperform | $7 |
| 2022-03-23 | down | Piper Sandler | Overweight → Neutral | $4 |
| 2022-03-11 | main | Piper Sandler | — → Overweight | $15 |
| 2022-03-11 | main | SVB Leerink | — → Outperform | $11 |
| 2022-02-16 | main | SVB Leerink | — → Outperform | $10 |
| 2022-01-07 | down | JP Morgan | Overweight → Neutral | $12 |
| 2022-01-07 | main | SVB Leerink | — → Outperform | $15 |
- ALIGOS THERAPEUTICS ($ALGS) Releases Q4 2025 Earnings - Quiver Quantitative hu, 05 Mar 2026 13
- Big loss reduction as Aligos (NASDAQ: ALGS) advances HBV and obesity pipeline - Stock Titan hu, 05 Mar 2026 13
- Wall Street Analysts Predict a 983.24% Upside in Aligos Therapeutics (ALGS): Here's What You Should Know - Nasdaq ue, 19 Aug 2025 07
- Aligos Therapeutics Earnings Report: Q4 Overview - Benzinga hu, 05 Mar 2026 13
- Can Aligos Therapeutics Stock Recover If Markets Fall? - Trefis Sun, 21 Dec 2025 08
- Trading the Move, Not the Narrative: (ALGS) Edition - Stock Traders Daily hu, 19 Feb 2026 09
- Aligos Therapeutics stock rises on Phase 2 HBV study progress - Investing.com Wed, 21 Jan 2026 08
- Aligos data hint at high hepatitis B viral suppression, new COVID protease drug - Stock Titan Mon, 23 Feb 2026 08
- Aligos Therapeutics (ALGS) Awards Stock Options to New Employees - GuruFocus Fri, 30 Jan 2026 08
- Here's Why Aligos Therapeutics (NASDAQ:ALGS) Must Use Its Cash Wisely - Yahoo Finance Wed, 07 Jan 2026 08
- Aligos Therapeutics Stock Rockets 57% With 7-Day Winning Streak - Trefis ue, 25 Nov 2025 08
- Aligos Therapeutics, Inc. Reports Positive Data from CROI Presentations on Pevifoscorvir Sodium and ALG-097558 - Quiver Quantitative Mon, 23 Feb 2026 08
- UBS Initiates Coverage of Aligos Therapeutics (ALGS) with Buy Recommendation - Nasdaq Wed, 07 Jan 2026 08
- A Peek at Aligos Therapeutics's Future Earnings - Benzinga Wed, 04 Mar 2026 20
- Global drug launch veteran to build hepatitis B commercial team at Aligos - Stock Titan ue, 13 Jan 2026 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -9.69M | -455.49K | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -40.40M | -82.89M | -93.91M | -124.54M |
| TotalUnusualItems | -46.13M | -2.17M | ||
| TotalUnusualItemsExcludingGoodwill | -46.13M | -2.17M | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -131.21M | -87.68M | -96.05M | -128.33M |
| ReconciledDepreciation | 2.62M | 3.07M | 3.67M | 3.78M |
| EBITDA | -86.53M | -85.06M | -93.91M | -124.54M |
| EBIT | -89.15M | -88.13M | -97.58M | -128.32M |
| NetInterestIncome | 4.41M | 3.41M | 1.64M | 132.00K |
| InterestIncome | 1.24M | 1.64M | 132.00K | |
| NormalizedIncome | -94.77M | -85.97M | -96.05M | -128.33M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -131.21M | -87.68M | -96.05M | -128.33M |
| TotalExpenses | 93.10M | 103.66M | 111.49M | 132.68M |
| TotalOperatingIncomeAsReported | -89.15M | -88.13M | -97.58M | -128.32M |
| DilutedAverageShares | 6.26M | 2.56M | 1.71M | 1.59M |
| BasicAverageShares | 6.26M | 2.56M | 1.71M | 1.59M |
| DilutedEPS | -20.94 | -34.20 | -56.25 | -80.50 |
| BasicEPS | -20.94 | -34.20 | -56.25 | -80.50 |
| DilutedNIAvailtoComStockholders | -131.21M | -87.68M | -96.05M | -128.33M |
| NetIncomeCommonStockholders | -131.21M | -87.68M | -96.05M | -128.33M |
| NetIncome | -131.21M | -87.68M | -96.05M | -128.33M |
| NetIncomeIncludingNoncontrollingInterests | -131.21M | -87.68M | -96.05M | -128.33M |
| NetIncomeContinuousOperations | -131.21M | -87.68M | -96.05M | -128.33M |
| TaxProvision | 331.00K | 795.00K | 106.00K | 143.00K |
| PretaxIncome | -130.88M | -86.88M | -95.94M | -128.19M |
| OtherIncomeExpense | -46.13M | -2.17M | ||
| GainOnSaleOfSecurity | -46.13M | -2.17M | ||
| NetNonOperatingInterestIncomeExpense | 4.41M | 3.41M | 1.64M | 132.00K |
| TotalOtherFinanceCost | -4.41M | -3.41M | ||
| InterestIncomeNonOperating | 1.24M | 1.64M | 132.00K | |
| OperatingIncome | -89.15M | -88.13M | -97.58M | -128.32M |
| OperatingExpense | 93.10M | 103.66M | 111.49M | 132.68M |
| ResearchAndDevelopment | 70.27M | 73.04M | 85.08M | 104.15M |
| SellingGeneralAndAdministration | 22.83M | 30.62M | 26.41M | 28.53M |
| GeneralAndAdministrativeExpense | 22.83M | 30.62M | 26.41M | 28.53M |
| OtherGandA | 22.83M | 30.62M | 26.41M | 28.53M |
| TotalRevenue | 3.94M | 15.53M | 13.91M | 4.36M |
| OperatingRevenue | 3.94M | 15.53M | 13.91M | 4.36M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 3.86M | 3.00M | 1.72M | 1.71M |
| ShareIssued | 3.86M | 3.00M | 1.72M | 1.71M |
| TotalDebt | 8.38M | 11.14M | 12.57M | 14.46M |
| TangibleBookValue | -28.97M | 92.08M | 103.90M | 184.73M |
| InvestedCapital | -28.97M | 92.08M | 103.90M | 184.73M |
| WorkingCapital | 40.40M | 117.18M | 100.42M | 165.47M |
| NetTangibleAssets | -28.97M | 92.08M | 103.90M | 184.73M |
| CapitalLeaseObligations | 8.38M | 11.14M | 12.57M | 14.46M |
| CommonStockEquity | -28.97M | 92.08M | 103.90M | 184.73M |
| TotalCapitalization | -28.97M | 92.08M | 103.90M | 184.73M |
| TotalEquityGrossMinorityInterest | -28.97M | 92.08M | 103.90M | 184.73M |
| StockholdersEquity | -28.97M | 92.08M | 103.90M | 184.73M |
| GainsLossesNotAffectingRetainedEarnings | 451.00K | 545.00K | 401.00K | 452.00K |
| OtherEquityAdjustments | 451.00K | 545.00K | 401.00K | 452.00K |
| RetainedEarnings | -618.01M | -486.80M | -399.12M | -303.07M |
| AdditionalPaidInCapital | 588.58M | 578.33M | 502.61M | 487.35M |
| CapitalStock | 8.00K | 7.00K | 4.00K | 4.00K |
| CommonStock | 8.00K | 7.00K | 4.00K | 4.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 99.07M | 59.45M | 42.79M | 50.64M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 77.33M | 35.54M | 9.66M | 11.68M |
| OtherNonCurrentLiabilities | 46.00K | 46.00K | 133.00K | |
| DerivativeProductLiabilities | 72.37M | 27.60M | 0.00 | |
| NonCurrentDeferredLiabilities | 0.00 | 233.00K | 0.00 | |
| NonCurrentDeferredRevenue | 0.00 | 233.00K | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 4.92M | 7.90M | 9.43M | 11.55M |
| LongTermCapitalLeaseObligation | 4.92M | 7.90M | 9.43M | 11.55M |
| CurrentLiabilities | 21.74M | 23.91M | 33.13M | 38.96M |
| OtherCurrentLiabilities | 66.00K | 276.00K | ||
| CurrentDeferredLiabilities | 151.00K | 1.31M | 9.21M | 7.64M |
| CurrentDeferredRevenue | 151.00K | 1.31M | 9.21M | 7.64M |
| CurrentDebtAndCapitalLeaseObligation | 3.46M | 3.24M | 3.14M | 2.91M |
| CurrentCapitalLeaseObligation | 3.46M | 3.24M | 3.14M | 2.91M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 6.39M | 6.67M | 6.30M | 6.33M |
| PayablesAndAccruedExpenses | 11.74M | 12.69M | 14.41M | 21.80M |
| CurrentAccruedExpenses | 7.70M | 9.66M | 1.47M | 1.24M |
| Payables | 4.04M | 3.03M | 12.94M | 20.57M |
| OtherPayable | 1.47M | 511.00K | 8.20M | 17.55M |
| AccountsPayable | 2.57M | 2.52M | 4.74M | 3.02M |
| TotalAssets | 70.09M | 151.53M | 146.69M | 235.37M |
| TotalNonCurrentAssets | 7.95M | 10.44M | 13.15M | 30.95M |
| OtherNonCurrentAssets | 627.00K | 625.00K | 634.00K | 866.00K |
| InvestmentsAndAdvances | 0.00 | 15.11M | ||
| InvestmentinFinancialAssets | 0.00 | 15.11M | ||
| AvailableForSaleSecurities | 15.11M | |||
| NetPPE | 7.33M | 9.82M | 12.51M | 14.97M |
| AccumulatedDepreciation | -11.78M | -10.76M | -9.57M | -7.26M |
| GrossPPE | 19.11M | 20.57M | 22.08M | 22.23M |
| Leases | 6.10M | 6.10M | 6.09M | 5.94M |
| ConstructionInProgress | 4.00K | 4.00K | 22.00K | 22.00K |
| OtherProperties | 10.94M | 12.39M | 13.88M | 14.50M |
| MachineryFurnitureEquipment | 2.06M | 2.08M | 2.10M | 1.77M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 62.14M | 141.08M | 133.54M | 204.42M |
| OtherCurrentAssets | 5.09M | 5.31M | 7.60M | 13.53M |
| RestrictedCash | 110.00K | 70.00K | 115.00K | 164.00K |
| CashCashEquivalentsAndShortTermInvestments | 56.94M | 135.70M | 125.83M | 190.73M |
| OtherShortTermInvestments | 19.94M | 0.00 | 44.48M | 3.92M |
| CashAndCashEquivalents | 37.00M | 135.70M | 81.35M | 186.82M |
| CashEquivalents | 37.00M | 135.70M | 81.35M | 186.82M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -80.87M | -79.02M | -80.33M | -116.55M |
| RepaymentOfDebt | -83.00K | -96.00K | -61.00K | -79.00K |
| IssuanceOfCapitalStock | 0.00 | 17.44M | 0.00 | 78.58M |
| CapitalExpenditure | -130.00K | -19.00K | -943.00K | -892.00K |
| InterestPaidSupplementalData | 0.00 | 0.00 | ||
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | ||
| EndCashPosition | 37.11M | 135.77M | 81.46M | 186.98M |
| BeginningCashPosition | 135.77M | 81.46M | 186.98M | 220.94M |
| ChangesInCash | -98.67M | 54.31M | -105.52M | -33.96M |
| FinancingCashFlow | 355.00K | 88.33M | 164.00K | 78.68M |
| CashFlowFromContinuingFinancingActivities | 355.00K | 88.33M | 164.00K | 78.68M |
| NetOtherFinancingCharges | -875.00K | |||
| ProceedsFromStockOptionExercised | 438.00K | 70.98M | 225.00K | 1.05M |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 0.00 | 17.44M | 0.00 | 78.58M |
| CommonStockIssuance | 0.00 | 17.44M | 0.00 | 78.58M |
| NetIssuancePaymentsOfDebt | -83.00K | -96.00K | -61.00K | -79.00K |
| NetLongTermDebtIssuance | -83.00K | -96.00K | -61.00K | -79.00K |
| LongTermDebtPayments | -83.00K | -96.00K | -61.00K | -79.00K |
| InvestingCashFlow | -18.28M | 44.98M | -26.29M | 3.02M |
| CashFlowFromContinuingInvestingActivities | -18.28M | 44.98M | -26.29M | 3.02M |
| NetInvestmentPurchaseAndSale | -18.15M | 45.00M | -25.35M | 3.91M |
| SaleOfInvestment | 90.00M | 45.01M | 78.92M | 23.00M |
| PurchaseOfInvestment | -108.15M | -11.00K | -104.27M | -19.09M |
| NetPPEPurchaseAndSale | -130.00K | -19.00K | -943.00K | -892.00K |
| PurchaseOfPPE | -130.00K | -19.00K | -943.00K | -892.00K |
| OperatingCashFlow | -80.74M | -79.00M | -79.39M | -115.66M |
| CashFlowFromContinuingOperatingActivities | -80.74M | -79.00M | -79.39M | -115.66M |
| ChangeInWorkingCapital | -4.96M | -9.53M | -1.55M | -4.65M |
| ChangeInOtherWorkingCapital | -1.16M | -8.13M | 2.50M | -4.36M |
| ChangeInOtherCurrentLiabilities | -2.68M | -2.39M | -1.95M | -1.65M |
| ChangeInOtherCurrentAssets | 216.00K | 2.30M | 5.32M | -8.07M |
| ChangeInPayablesAndAccruedExpense | -1.33M | -1.30M | -7.42M | 9.43M |
| ChangeInAccruedExpense | -1.39M | 918.00K | -9.14M | 9.74M |
| ChangeInPayable | 54.00K | -2.22M | 1.72M | -313.00K |
| ChangeInAccountPayable | 54.00K | -2.22M | 1.72M | -313.00K |
| StockBasedCompensation | 8.45M | 12.65M | 14.69M | 13.46M |
| AssetImpairmentCharge | 0.00 | 724.00K | 0.00 | |
| AmortizationOfSecurities | -1.78M | -424.00K | -159.00K | 86.00K |
| DepreciationAmortizationDepletion | 2.62M | 3.07M | 3.67M | 3.78M |
| DepreciationAndAmortization | 2.62M | 3.07M | 3.67M | 3.78M |
| Depreciation | 2.62M | 3.07M | 3.67M | 3.78M |
| OperatingGainsLosses | 46.13M | 2.19M | ||
| GainLossOnInvestmentSecurities | 46.13M | 2.17M | ||
| NetIncomeFromContinuingOperations | -131.21M | -87.68M | -96.05M | -128.33M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ALGS
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|